Laura Goederle

Laura Goederle

Auto-generated profile, based on publicly available information

Laura Goederle

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MPMarie Piollet
Marie Piollet
FPFlorentina Porsch
Florentina Porsch
GRGiuseppe Rizzo
Giuseppe Rizzo
FKFrederieke Kapser
Frederieke Kapser
DSDirk J. J. Schulz
Dirk J. J. Schulz
CCClément Cochain
Clément Cochain
Atherosclerosis is a chronic disease of the vascular wall driven by lipid accumulation and inflammation in the intimal layer of arteries, and its main complications—myocardial infarction and stroke—are the leading cause of mortality worldwide1,2. Recent studies have identified triggering receptor expressed on myeloid cells 2 (TREM2), a lipid-sensing receptor regulating myeloid cell functions3, to be highly expressed in macrophage foam cells in experimental and human atherosclerosis4. However, the role of TREM2 in atherosclerosis is not fully known. Here we show that hematopoietic or global TREM2 deficiency increased, whereas TREM2 agonism decreased, necrotic core formation in early atherosclerosis. We demonstrate that TREM2 is essential for the efferocytosis capacities of macrophages and to the survival of lipid-laden macrophages, indicating a crucial role of TREM2 in maintaining the balance between foam cell death and clearance of dead cells in atherosclerotic lesions, thereby controlling plaque necrosis.

25 August 2021 in Nature
Verified
Journal Article
Closed access
PDF file
DTDimitrios Tsiantoulas
Dimitrios Tsiantoulas
MEMahya Eslami
Mahya Eslami
GOGeorg Obermayer
Georg Obermayer
MCMarc Clement
Marc Clement
DSDiede Smeets
Diede Smeets
CBChristoph J. Binder
Christoph J. Binder

11 March 2021 in Blood
Verified
Journal Article
Closed access
PDF file
GOGeorg Obermayer
Georg Obermayer
TATaras Afonyushkin
Taras Afonyushkin
LGLaura Goederle
Laura Goederle
FPFlorian Puhm
Florian Puhm
WSWaltraud C. Schrottmaier
Waltraud C. Schrottmaier
CBChristoph J. Binder
Christoph J. Binder
Thrombosis and the complications associated with it are a major cause of morbidity and mortality worldwide. Microvesicles (MVs), a class of extracellular vesicles, are increasingly recognized as mediators of coagulation and biomarkers of thrombotic risk. Thus, identifying factors targeting MV-driven coagulation may help in the development of novel antithrombotic treatments. We have previously identified a subset of circulating MVs that is characterized by the presence of oxidation-specific epitopes and bound by natural IgM antibodies targeting these structures. Here, we investigated whether natural IgM antibodies, which are known to have important anti-inflammatory house-keeping functions, inhibit the procoagulatory properties of MVs. We found that the extent of plasma coagulation is inversely associated with the levels of both free and MV-bound endogenous IgM. Moreover, the oxidation epitope-specific natural IgM antibody LR04, which recognizes malondialdehyde adducts, reduced MV-dependent plasmatic coagulation and whole blood clotting without affecting thrombocyte aggregation. Intravenous injection of LR04 protected mice from MV-induced pulmonary thrombosis. Of note, LR04 competed the binding of coagulation factor X/Xa to MVs, providing a mechanistic explanation for its anticoagulatory effect. Thus, our data identify natural IgM antibodies as hitherto unknown modulators of MV-induced coagulation in vitro and in vivo and their prognostic and therapeutic potential in the management of thrombosis.

27 January 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Max LenzMax Lenz
Max Lenz
CKChristoph Kaun
Christoph Kaun
KKKonstantin A. Krychtiuk
Konstantin A. Krychtiuk
PHPatrick Haider
Patrick Haider
MBMira Brekalo
Mira Brekalo
WSWalter S. Speidl
Walter S. Speidl
Nicorandil, a balanced vasodilator, is used in the second-line therapy of angina pectoris. In this study, we aimed to illuminate the effects of nicorandil on inflammation, apoptosis, and atherosclerotic plaque progression. Twenty-five LDL-R -/- mice were fed a high-fat diet for 14 weeks. After 6 weeks mice were randomly allocated to treatment with nicorandil (10 mg/kg/day) or tap water. Nicorandil treatment led to a more stable plaque phenotype, displaying an increased thickness of the fibrous cap (p = 0.014), a significant reduction in cholesterol clefts (p = 0.045), and enhanced smooth muscle cell content (p = 0.009). In endothelial cells nicorandil did not reduce the induction of adhesion molecules or proinflammatory cytokines. In H2O2 challenged endothelial cells, pretreatment with nicorandil significantly reduced the percentage of late apoptotic/necrotic cells (p = 0.016) and the ratio of apoptotic to living cells (p = 0.036). Atherosclerotic lesions of animals treated with nicorandil exhibited a significantly decreased content of cleaved caspase-3 (p = 0.034), lower numbers of apoptotic nuclei (p = 0.040), and reduced 8-oxogunanine staining (p = 0.039), demonstrating a stabilizing effect of nicorandil in established atherosclerotic lesions. We suggest that nicorandil has a positive effect on atherosclerotic plaque stabilization by reducing apoptosis.

13 July 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
Max LenzMax Lenz
Max Lenz
Manuel SalzmannManuel Salzmann
Manuel Salzmann
CCCosmin I. Ciotu
Cosmin I. Ciotu
CKChristoph Kaun
Christoph Kaun
KKKonstantin A. Krychtiuk
Konstantin A. Krychtiuk
WSWalter S. Speidl
Walter S. Speidl
Changes in Ca2+influx during proinflammatory stimulation modulates cellular responses, including the subsequent activation of inflammation. Whereas the involvement of Ca2+has been widely acknowledged, little is known about the role of Na+. Ranolazine, a piperazine derivative and established antianginal drug, is known to reduce intracellular Na+as well as Ca2+levels. In stable coronary artery disease patients (n= 51) we observed reduced levels of high-sensitive C-reactive protein (CRP) 3 mo after the start of ranolazine treatment (n= 25) as compared to the control group. Furthermore, we found that in 3,808 acute coronary syndrome patients of the MERLIN‐TIMI 36 trial, individuals treated with ranolazine (1,934 patients) showed reduced CRP values compared to placebo-treated patients. The antiinflammatory effects of sodium modulation were further confirmed in an atherosclerotic mouse model. LDL−/−mice on a high-fat diet were treated with ranolazine, resulting in a reduced atherosclerotic plaque burden, increased plaque stability, and reduced activation of the immune system. Pharmacological Na+inhibition by ranolazine led to reduced express of adhesion molecules and proinflammatory cytokines and reduced adhesion of leukocytes to activated endothelium both in vitro and in vivo. We demonstrate that functional Na+shuttling is required for a full cellular response to inflammation and that inhibition of Na+influx results in an attenuated inflammatory reaction. In conclusion, we demonstrate that inhibition of Na+–Ca2+exchange during inflammation reduces the inflammatory response in human endothelial cells in vitro, in a mouse atherosclerotic disease model, and in human patients.